Colombia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Description

List of Tables

GlobalData, the industry analysis specialist, has released its latest report: "Colombia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Colombia. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

The Colombian pharmaceutical market has growth potential in Latin America due to qualified human resources, good manufacturing practices (GMP), and quality pharmaceutical products. Colombia's pharmaceutical market was worth $4.3 billion in 2014, which increased at a Compound Annual Growth Rate (CAGR) of 2.1% to $4.8 billion in 2019 in terms of US dollars. The market value is expected to reach $5.7 billion by 2027. In Latin America, Colombia ranks third in the medical device market, after Brazil and Mexico. The medical device market in Colombia was calculated as $2.3 million in 2019. In 2019, Colombia Productiva released the pharmaceutical industry business plan for providing a roadmap for the growth of the pharma industry by 2032. This plan aims for Colombia to be a leader in the manufacturing and distribution of medicines to meet local needs based on public health needs, and serve as a major distributor of drugs across the South American continent.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Colombia, and includes -

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
Profiles and SWOT analyses of the major players in the pharmaceutical market: Sanofi, Bayer, Merck, GlaxoSmithKline (GSK), Genomma Lab, and Biopas.
Profiles and SWOT analyses of the major players in the medical device market: Roche, Abbott, Medtronic, Fresenius, and Siemens Healthineers.
An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country's healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices.
Detailed analysis of the country's healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure.
An overview of the opportunities for and challenges to growth in the Colombian healthcare market.

Reasons to Buy

This report will enhance your decision-making capability by allowing you to -

Develop business strategies by understanding the trends shaping and driving the Colombian healthcare market
Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact the Colombian healthcare market in the future
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors' performance
Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Product Code: GDHC0034CHR

1. Table of Contents

1.1List of Figures
1.2 List of Tables

2. Executive Summary

2.1 Executive Summary
2.2 Key Highlights - Facts about the Colombian Healthcare Market
2.3 Key Highlights: Healthcare Startups in Colombia
2.4 Key Events: Colombian Healthcare Timeline, 2015-21
2.5 Key Events: Colombian Pharmaceutical Market
2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020-22
2.7 Key Events: Mergers and Acquisitions
2.8 Country Profile, Colombia, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market - Overview
3.2 Pharmaceutical Market - Exports
3.3 Pharmaceutical Market - Imports
3.4 Pharmaceutical Market - Supply Channels, Colombia
3.5 Pharmaceutical Market - Market Segments
3.6 Major Therapeutic Areas, Colombia
3.7 COVID-19 Epidemiology, Colombia
3.8 COVID-19 Impact and Developments in the Healthcare Market, Colombia
3.9 COVID-19 Clinical Trials Landscape, Colombia
3.10 Pharmaceutical Market - Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market - Overview
4.2 Medical Devices Market - Major Players

5. Pharmaceutical and Medical Devices Market - Drivers and Barriers

5.1 Drivers
5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Colombia, 2016-22
6.2 Deal Analysis: Medical Device Market, Colombia, 2016-22

7. HealthTech Landscape

7.1 HealthTech Landscape, Colombia
7.2 HealthTech Deals Landscape, Colombia
7.3 Key HealthTech Deals, Colombia
7.4 Adoption of Technology in Healthcare, Colombia
7.5 Digital Regulations, Colombia
7.6 HealthTech Landscape: Benefits and Risks, Colombia

8. Market Access

8.1 Overview of Healthcare System, Colombia
8.2 Reimbursement Process, Colombia
8.3 Overview of Insurance Providers, Colombia
8.4 Reimbursement Landscape, Colombia
8.5 Healthcare Spending and Prescription Drug Price Trend, Colombia
8.6 Pricing Policies, Colombia
8.7 Market Access: Key Events Timeline, Colombia, 2010-21
8.8 Regulatory Landscape, Colombia
- 8.8.1 Marketing Authorization for Pharmaceutical Products, Colombia
- 8.8.2 Marketing Authorization for Biologics, Colombia
- 8.8.3 Marketing Authorization for Medical Devices, Colombia
- 8.8.4 Intellectual Property Rights, Patent, Colombia
- 8.8.5 Intellectual Property Rights, Trademark, Colombia
- 8.8.6 Clinical Trial Regulation Process, Colombia
- 8.8.7 Pharmaceutical Clinical Trials Landscape, Colombia
- 8.8.8 Medical Device Clinical Trials Landscape, Colombia
- 8.8.9 Pharmaceutical Manufacturing and Licensing, Colombia
- 8.8.10 Pharmaceutical Export and Import, Colombia
- 8.8.11 Pharmaceutical Advertising Regulations, Colombia
- 8.8.12 Pharmacy Regulations, Colombia
- 8.8.13 Labeling and Packaging Regulations, Colombia

9. Country Healthcare Landscape

9.1 Colombian Healthcare Policy Highlights
9.2 Healthcare Facilities, Colombia
9.3 Healthcare Resources, Colombia
9.4 Life Expectancy and Immunization Rate, Colombia
9.5 Environmental Health, Colombia
9.6 Healthcare Personnel, Colombia
9.7 Disease Burden, Colombia
9.8 Healthcare Expenditure, Colombia

10 Trade Associations, Colombia

11 Trade Fairs, Colombia

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology
- 13.1.1 Coverage
- 13.1.2 Secondary Research
- 13.1.3 Forecasts
13.2 Bibliography
13.3 About GlobalData
13.4 Contact Us
13.5 Disclaimer

Product Code: GDHC0034CHR

List of Tables

Table 1: COVID-19 indicators (number of cases), Global and Colombia, 2022
Table 2: COVID-19-related travel restrictions, Colombia, 2020-22
Table 3: Available COVID-19 IVD products, Colombia, 2020-22
Table 4: COVID-19 vaccines trials, Colombia, 2022
Table 5: COVID-19 approved vaccines, Colombia, 2022
Table 6: Pipeline COVID-19 products, Colombia, 2020-22
Table 7: Digital applications launched through MinSalud, Colombia, 2022
Table 8: Classification of medical devices, Colombia, 2022
Table 9: Patent approval fees, Colombia, 2021
Table 10: Trade fairs, Colombia, 2022

List of Figures

Figure 1: Pharmaceutical market, revenue ($M), Colombia, 2014-21
Figure 2: Medical devices market, revenue ($M), Colombia, 2013-19
Figure 3: Healthcare start-ups in Colombia, 2022
Figure 4: Country profile, Colombia, 2021
Figure 5: Pharmaceutical market, revenue ($M), Colombia, 2014-21
Figure 6: Pharmaceutical market, revenue forecast ($M), Colombia, 2022-27
Figure 7: Pharmaceutical exports ($M), Colombia, 2013-20
Figure 8: Top export partners, Colombia, 2020
Figure 9: Pharmaceutical imports ($B), Colombia, 2013-20
Figure 10: Top import partners, Colombia, 2020
Figure 11: Pharmaceutical supply channel, Colombia, 2022
Figure 12: Process of INVIMA against fraud medicines complaints, Colombia, 2022
Figure 13: OTC medicines market ($M), major distribution channels, Colombia, 2021
Figure 14: OTC market revenue ($M), Colombia, 2013-21
Figure 15: OTC medicines market ($M), major categories, Colombia, 2021
Figure 16: Major therapeutic areas of ATC1 anatomical group by pharmaceutical sale, Colombia, 2019
Figure 17: COVID-19 cases, Colombia, 2020-22
Figure 18: COVID-19 deaths, Colombia, 2020-22
Figure 19: COVID-19 stringency index, Colombia, 2020-22
Figure 20: COVID-19 containment and health index, Colombia, 2020-22
Figure 21: COVID-19 vaccine doses administration, number of vaccine doses administered, Colombia, 2022
Figure 22: COVID-19 vaccine booster doses administration, number of booster doses administered per 100 people, Colombia, 2022
Figure 23: COVID-19 fiscal stimulus timeline, Colombia, 2020-22
Figure 24: Objectives of National Vaccination Plan, Colombia, 2022
Figure 25: COVID-19 vaccination plan, Colombia, 2022
Figure 26: PRASS model, Colombia, 2022
Figure 27: COVID-19 vaccine distribution logistics as defined by the Ministry, Colombia 2022
Figure 28: Regulations governing COVID-19 vaccination, Colombia, 2022
Figure 29: COVID-19 clinical trials count by trial status, Colombia, 2021-22
Figure 30: COVID-19 clinical trials count by trial phase, Colombia, 2021-22
Figure 31: Top COVID-19 clinical trials sponsors by trial count, Colombia, 2021-22
Figure 32: Major pharmaceutical companies by operational income ($M), Colombia, 2020
Figure 33: Medical devices market, revenue ($M), Colombia, 2013-19
Figure 34: Medical devices market, revenue ($B) of major companies, Colombia, 2021
Figure 35: Deal value and deal count, pharmaceutical market, Colombia, 2016-22
Figure 36: Deal value and deal count subtypes, pharmaceutical market, Colombia, 2016-22
Figure 37: Deal value and deal count, quarterly, pharmaceutical market, Colombia, 2016-22
Figure 38: Top therapy areas by deal value ($M), pharmaceutical market, Colombia, 2016-22
Figure 39: Top therapy areas by deal count, pharmaceutical market, Colombia, 2016-22
Figure 40: M&A deals by quarter, pharmaceutical market, Colombia, 2016-22 (by value and by number)
Figure 41: PE deals by quarter, pharmaceutical market, Colombia, 2016-22 (by value and by number)
Figure 42: Deal value and deal count, medical devices market, Colombia, 2016-22
Figure 43: Deal value and deal count subtypes, medical devices market, Colombia, 2016-22
Figure 44: Deal value and deal count, quarterly, medical devices market, Colombia, 2016-22
Figure 45: Top equipment sectors by deal value ($M), medical devices market, Colombia, 2016-22
Figure 46: Top equipment sectors by deal count, medical devices market, Colombia, 2016-22
Figure 47: M&A deals by half-year, medical devices market, Colombia, 2016-22 (by value and by number)
Figure 48: VC deals by quarter, medical devices market, Colombia, 2016-22 (by value and by number)
Figure 49: Process of providing digital services to citizens, Colombia, 2022
Figure 50: Deal value ($M) and deal count, HealthTech, Colombia, 2015-22
Figure 51: Deal value ($M) and deal count by sector, HealthTech, Colombia, 2015-22
Figure 52: Component, transverse enablers and purpose of digital government policy, Colombia, 2022
Figure 53: Composition of healthcare system, Colombia, 2022
Figure 54: Composition of health system, Colombia, 2022
Figure 55: Number of POS medicines undergoing patent expiry during 2022-27, Colombia, 2022
Figure 56: POS medicines undergoing patent expiration, Colombia, 2022
Figure 57: OOP expenditure (% of total expenditure on health), Colombia, 2013-21
Figure 58: Change in price trend in the healthcare sector (in %), Colombia, 2016-20
Figure 59: Organization of INVIMA, Colombia, 2022
Figure 60: Procedure of marketing authorization of new pharmaceutical drugs, Colombia, 2022
Figure 61: Procedure of marketing authorization of new drug under pharmacological standards, Colombia, 2022
Figure 62: Regulatory pathway for biologics through complete dossier approach, Colombia, 2022
Figure 63: Regulatory pathway for biologics through abbreviated comparability approach, Colombia, 2022
Figure 64: Regulatory pathway for biologics through comparability approach, Colombia, 2022
Figure 65: Procedure of marketing authorization of medical devices, Colombia, 2022
Figure 66: Procedure of obtaining the automatic health registration for medical devices, Colombia, 2022
Figure 67: Patent approval process, Colombia, 2022
Figure 68: Pharmaceutical clinical trials count by trial status, Colombia, 2021-22
Figure 69: Pharmaceutical clinical trials count by indication, Colombia, 2021-22
Figure 70: Pharmaceutical clinical trials count by phase, Colombia, 2021-22
Figure 71: Top five pharmaceutical clinical trials sponsors by count, Colombia, 2021-22
Figure 72: Medical devices clinical trials count by trial status, Colombia, 2021-22
Figure 73: Medical devices clinical trials count by market categories, Colombia, 2021-22
Figure 74: Medical devices clinical trials count by therapeutic areas, Colombia, 2021-22
Figure 75: Medical devices clinical trials sponsors by count, Colombia, 2021-22
Figure 76: Process for issuing manufacturing license, Colombia, 2022
Figure 77: Labeling requirements, Colombia, 2022
Figure 78: Sustainable development goals under good health and well being, Colombia, 2022
Figure 79: Number of government hospitals, Colombia, 2015-21
Figure 80: Number of diagnostic units, Colombia, 2013-21
Figure 81: Hospital beds (per 1,000 population), Colombia, 2013-21
Figure 82: Acute care hospital beds (per 1,000 population), Colombia, 2013-21
Figure 83: Psychiatric care hospital beds (per 100 population), Colombia, 2013-21
Figure 84: Life expectancy at birth (years), Colombia, 2013-21